125 related articles for article (PubMed ID: 34763479)
21. Anorectal malignant melanoma. A clinicopathologic study, including immunohistochemistry and DNA flow cytometry.
Ben-Izhak O; Levy R; Weill S; Groisman G; Cohen H; Stajerman S; Misselevich I; Nitecky S; Eidelman S; Kerner H
Cancer; 1997 Jan; 79(1):18-25. PubMed ID: 8988722
[TBL] [Abstract][Full Text] [Related]
22. Anorectal malignant melanoma: retrospective analysis of management and outcome in a single Portuguese Institution.
Miguel I; Freire J; Passos MJ; Moreira A
Med Oncol; 2015 Jan; 32(1):445. PubMed ID: 25502089
[TBL] [Abstract][Full Text] [Related]
23. Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases.
Dodds TJ; Wilmott JS; Jackett LA; Lo SN; Long GV; Thompson JF; Scolyer RA
Pathology; 2019 Jan; 51(1):39-45. PubMed ID: 30497801
[TBL] [Abstract][Full Text] [Related]
24. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
[TBL] [Abstract][Full Text] [Related]
25. ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies.
Matsumoto A; Nakashima C; Kimura S; Sueoka E; Aragane N
BMC Cancer; 2021 May; 21(1):584. PubMed ID: 34022841
[TBL] [Abstract][Full Text] [Related]
26.
Parakh S; Musafer A; Paessler S; Witkowski T; Suen CSNLW; Tutuka CSA; Carlino MS; Menzies AM; Scolyer RA; Cebon J; Dobrovic A; Long GV; Klein O; Behren A
Front Immunol; 2021; 12():672521. PubMed ID: 34177913
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma.
Nanamori H; Sawada Y
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163049
[TBL] [Abstract][Full Text] [Related]
28. [A case report of long-term survival in the patient with anorectal malignant melanoma].
Yokota K; Takahashi M; Okada K; Ishizu H; Masuko H; Tanaka K; Hata T; Kawamura H; Yamagami H; Watarai H; Tanioka T
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2045-7. PubMed ID: 22202279
[TBL] [Abstract][Full Text] [Related]
29. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
30. Anorectal Mucosal Melanoma: A Case Report and Literature Review.
de Meira Júnior JD; Sobrado LF; Guzela VM; Nahas SC; Sobrado CW
Am J Case Rep; 2021 Oct; 22():e933032. PubMed ID: 34699518
[TBL] [Abstract][Full Text] [Related]
31. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
[TBL] [Abstract][Full Text] [Related]
32. Anorectal malignant melanoma: report of two cases from Buddhachinnaraj Hospital.
Somran J; Kanngurn S; Porncharoenpong S; Lertkajornsin O
J Med Assoc Thai; 2005 Aug; 88(8):1128-33. PubMed ID: 16404844
[TBL] [Abstract][Full Text] [Related]
33. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
Danilova L; Wang H; Sunshine J; Kaunitz GJ; Cottrell TR; Xu H; Esandrio J; Anders RA; Cope L; Pardoll DM; Drake CG; Taube JM
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7769-E7777. PubMed ID: 27837027
[TBL] [Abstract][Full Text] [Related]
34. Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status.
Po JW; Ma Y; Balakrishna B; Brungs D; Azimi F; de Souza P; Becker TM
PLoS One; 2019; 14(2):e0211866. PubMed ID: 30735560
[TBL] [Abstract][Full Text] [Related]
35. Education and imaging. Gastrointestinal: anorectal malignant melanoma.
Yang JI; Byun HJ; Kang JM
J Gastroenterol Hepatol; 2009 Apr; 24(4):697. PubMed ID: 19368636
[No Abstract] [Full Text] [Related]
36. Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Toral KJ; Wuenschel MA; Black EP
PLoS One; 2021; 16(8):e0256416. PubMed ID: 34437586
[TBL] [Abstract][Full Text] [Related]
37. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
38. Genital and anorectal mucosal melanoma is associated with cutaneous melanoma in patients and in families.
Cazenave H; Maubec E; Mohamdi H; Grange F; Bressac-de Paillerets B; Demenais F; Avril MF
Br J Dermatol; 2013 Sep; 169(3):594-9. PubMed ID: 23647170
[TBL] [Abstract][Full Text] [Related]
39. [A Case of Anorectal Amelanotic Malignant Melanoma].
Hiraki S; Kuwahara T; Harada T; Kawaoka T; Fukuda S
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2256-8. PubMed ID: 26805329
[TBL] [Abstract][Full Text] [Related]
40. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
